Parabilis Medicines, Inc. Common Stock
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Parabilis Medicines, Inc. Common Stock is the equity of Parabilis Medicines, a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for serious diseases. The company uses its Helicon discovery platform to design stabilized peptides that can interact with proteins often considered difficult to target with conventional medicines. Its current pipeline includes programs aimed at intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical candidate, zolucatetide, designed to inhibit the β-catenin and TCF interaction in the Wnt/β-catenin signaling pathway. Parabilis Medicines serves the healthcare and life sciences sectors, with a particular emphasis on oncology and other diseases driven by complex protein signaling.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Mathai Mammen M.D., Ph.D.
- Employees
- 145
- Headquarters
- Cambridge, MA, United States
- Website
- parabilismed.com